Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study

PF-06804103 is an anti-HER2 antibody–drug conjugate with auristatin payload. We evaluated its safety, tolerability, and antitumor activity in patients with advanced/unresectable or metastatic breast and gastric cancers. This multicenter, open-label, first-in-human, phase 1 study (NCT03284723) compri...

Descripción completa

Detalles Bibliográficos
Autores principales: Meric-Bernstam, Funda, Calvo, Emiliano, Lee, Keun Seok, Moreno, Victor, Park, Yeon Hee, Rha, Sun Young, Chalasani, Pavani, Zhong, Wei, Zhou, Li, Pirie-Shepherd, Steven, Leung, Abraham C.F., Curigliano, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543980/
https://www.ncbi.nlm.nih.gov/pubmed/37420274
http://dx.doi.org/10.1158/1535-7163.MCT-23-0101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543980/
https://www.ncbi.nlm.nih.gov/pubmed/37420274
http://dx.doi.org/10.1158/1535-7163.MCT-23-0101

Ejemplares similares